Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
News|Podcasts|May 28, 2025
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
This segment takes a deeper dive into toxicity management—focusing not just on what to monitor, but how institutions are putting these protocols into action in real-world clinical settings.
Advertisement
Advertisement
Related to this article
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
FDA Grants Accelerated Approval to Ravulizumab for Proteinuria Reduction in IgA Nephropathy
4
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
5